Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of au...

 

 
 
 
Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of authorisation: 23/01/2006, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of authorisation: 23/01/2006, Revision: 19, Status: Authorised



 
 
 
Interview Kansrijke Start – Kansrijke Start in Meppel
Ondersteuning bieden aan zwangeren in een kwetsbare omgeving.



 
 
 
ECDC and EMA update recommendations on additional booster doses of COVID-19 vaccines
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) are recommending that second booster doses of COVID-19 vaccines be considered for people between 60 and 79 years old and people with medical conditions putting them at high risk of severe disease.


Actueel zorgnieuws in jouw mailbox ontvangen?
Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.